These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9459044

  • 1. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric-coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients.
    Thomson AB, Kirdeikis P, Lastiwka R, Röhss K, Sinclair P, Olofsson B.
    Can J Gastroenterol; 1997; 11(8):657-60. PubMed ID: 9459044
    [Abstract] [Full Text] [Related]

  • 2. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20 mg under repeated dose conditions.
    Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B.
    Can J Gastroenterol; 1997; 11(8):663-7. PubMed ID: 9459045
    [Abstract] [Full Text] [Related]

  • 3. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB, Fort JG, Zhang Y.
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [Abstract] [Full Text] [Related]

  • 4. Omeprazole--a new formulation.
    Armstrong D.
    Can J Gastroenterol; 1997 Jul; 11(8):655-6. PubMed ID: 9459043
    [No Abstract] [Full Text] [Related]

  • 5. Bioavailability of omeprazole 20 mg capsules containing omeprazole 22.5% enteric coated pellets versus a reference product in healthy Bangladeshi male subjects: an open-label, single-dose, randomized-sequence, two-way crossover study.
    Islam MS, Trini AB, Shohag H, Ahmed MU, Maruf AA, Hasnat A.
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):778-86. PubMed ID: 22122821
    [Abstract] [Full Text] [Related]

  • 6. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
    Doan TT, Wang Q, Griffin JS, Lukasik NL, O'Dea RF, Pan WJ.
    Am J Health Syst Pharm; 2001 Aug 15; 58(16):1512-9. PubMed ID: 11515348
    [Abstract] [Full Text] [Related]

  • 7. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule.
    Schaltenbrand R, Huber R, Cotoraci CA, Mascher H, Potthast H, Hole U.
    Int J Clin Pharmacol Ther; 2001 Oct 15; 39(10):453-9. PubMed ID: 11680670
    [Abstract] [Full Text] [Related]

  • 8. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
    Larson C, Cavuto NJ, Flockhart DA, Weinberg RB.
    Dig Dis Sci; 1996 Mar 15; 41(3):475-9. PubMed ID: 8617118
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
    Chun AH, Erdman K, Chiu YL, Pilmer BL, Achari R, Cavanaugh JH.
    Clin Ther; 2002 Aug 15; 24(8):1322-31. PubMed ID: 12240782
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the effect of orally administered acid suppressants on intragastric pH in cats.
    Parkinson S, Tolbert K, Messenger K, Odunayo A, Brand M, Davidson G, Peters E, Reed A, Papich MG.
    J Vet Intern Med; 2015 Jan 15; 29(1):104-12. PubMed ID: 25537303
    [Abstract] [Full Text] [Related]

  • 12. Bioequivalence assessment of two capsule formulations of omeprazole in healthy volunteers.
    Hussein RF, Lockyer M, Hammami MM.
    Arzneimittelforschung; 2007 Jan 15; 57(2):101-5. PubMed ID: 17396620
    [Abstract] [Full Text] [Related]

  • 13. Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers.
    Hasan A, Abul Kalam Azad M, Ullah MA, Mahbub Latif AH, Hasnat A.
    Int J Clin Pharmacol Ther; 2009 Mar 15; 47(3):215-21. PubMed ID: 19281731
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.
    Geus WP, Mathôt RA, Mulder PG, Lamers CB.
    Aliment Pharmacol Ther; 2000 Aug 15; 14(8):1057-64. PubMed ID: 10930900
    [Abstract] [Full Text] [Related]

  • 16. [Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers].
    Dong H.
    Zhonghua Nei Ke Za Zhi; 1999 Aug 15; 38(8):533-6. PubMed ID: 11798692
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration.
    Ehrlich A, Lücker PW, Wiedemann A, Sander P, Huber R, Mascher H.
    Methods Find Exp Clin Pharmacol; 1999 Aug 15; 21(1):47-51. PubMed ID: 10222447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.